ArticleFrontiers in physiology2025
Comprehensive biomarker profiling reveals distinct molecular signatures across stone types: a large-scale cross-sectional study in Southern China.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stone diseases represent a significant global health burden affecting 10%-15% of the population worldwide. Despite advances in diagnostic imaging, current approaches often lack the ability to predict stone formation or differentiate between stone types at early stages. Methods: This retrospective study analyzed data from 61,310 stone patients and 55,010 matched controls using 1:1 propensity score matching. Stone cases were categorized into five major groups and further subdivided by organ system. Comprehensive serum biomarker profiling was conducted using automated biochemistry analyzers. Results: Urinary system stones constituted the largest proportion (80.97%), followed by biliary system stones (21.12%). The study revealed distinct biomarker signatures: elevated serum creatinine and cystatin C in uric acid stones; increased PSA and monocyte counts in prostatic calculi; elevated β2-microglobulin and total bilirubin in common bile duct stones; and increased basophils, ceruloplasmin, ferritin, immunoglobulin-A, and rheumatoid factor in gallstones. Conclusion: This study represents the first comprehensive evaluation of stone-specific clinical biomarker patterns derived from routine laboratory parameters, providing potential diagnostic markers for different stone types and suggesting stone-specific pathophysiological mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.